Ironclad vs LinkSquares for Biotech Consultants: CDAs and MTAs

A CDA typically comes first, protecting whatever proprietary information a client shares before any real work begins. If the engagement involves handling physical samples or proprietary datasets, an MTA follows, defining what can be done with that material and, critically, who owns any findings derived from it. Only then does the actual services agreement get negotiated, covering scope, deliverables, and broader IP terms. Skipping or rushing any step in that sequence is where risk enters.

Client urgency often pushes consultants to start work before the CDA or MTA is fully executed, which is exactly the wrong moment to skip a step. Ironclad's workflow model helps enforce the sequence by routing each document through required approval before the next step, or actual work, begins, which matters most for firms fielding frequent inbound requests from clients eager to move fast.

A consulting firm running several concurrent client engagements needs to track, across dozens of CDAs and MTAs, which findings are jointly owned, which are client-owned with a license back to the consultant, and which are silent because a template got modified inconsistently. LinkSquares's repository analytics are built for exactly this kind of cross-document IP comparison, which becomes necessary once a firm's engagement count outpaces what any one person can track from memory.

• Client name and engagement start date
• CDA executed date and expiration or duration
• MTA required, and if so, executed date and material description
• IP ownership outcome for findings: consultant, client, or jointly owned
• Any publication restriction tied to the CDA or MTA

Building this as a simple tracked worksheet, whether inside a contract platform or a standalone spreadsheet, gives a firm a fast answer to "what did we agree to with this client" without re-reading three separate documents.

When the engagement touches FDA-regulated product development, the services agreement's scope language should clearly state that the consultant is providing regulatory strategy advice, not a guarantee of approval outcomes. This distinction matters both for client expectations and for the consultant's own liability exposure, and it's worth confirming with counsel that your standard scope language draws that line clearly.

Academic and research-adjacent biotech consulting engagements often carry a publication dimension that purely commercial consulting doesn't: a consultant or their client may want to publish findings derived from work covered under an MTA, and whether that's permitted, and under what review process, needs to be addressed in the MTA itself, not assumed. Publication restrictions in MTAs vary widely, some prohibit publication entirely without the material's originating institution reviewing the manuscript first, others allow it with a defined notice period, and a consultant who doesn't check this before submitting a paper can create a real problem for both themselves and their client.

Tracking which active and past engagements carry a publication restriction, and what that restriction actually requires, is exactly the kind of detail that gets lost if MTAs are filed away rather than actively tracked. A firm publishing findings regularly as part of its business development, thought leadership pieces, conference presentations, needs a reliable way to check, before submission, whether the underlying MTA allows it and what review process it requires.

This is a genuinely higher-stakes version of the general IP tracking problem this industry faces, since a publication restriction violation can damage a client relationship, and sometimes a firm's relationship with the material's originating institution, well beyond what a typical contract dispute would. Building this check into a firm's standard pre-publication process, not just its contract management practice, closes a gap that's easy to overlook under normal business pressure to publish and demonstrate expertise.

It's worth having someone specifically responsible for this pre-publication check rather than relying on the individual consultant preparing the paper to remember an MTA clause they may not have personally negotiated. A firm publishing regularly benefits from a short, standing checklist, confirm the governing MTA, confirm any required review window, confirm attribution requirements, run before any manuscript goes out, which turns a legal risk into a routine editorial step.